# EDGAR Filing Document

**Accession Number:** 0001698149
**File Stem:** 0001415889-25-019350
**Filing Date:** 2025-7
**Character Count:** 7735
**Document Hash:** cf0475a6c200226b472fb1c8ed872245
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-019350.hdr.sgml**: 20250703

**ACCESSION NUMBER**: 0001415889-25-019350

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250301

**FILED AS OF DATE**: 20250703

**DATE AS OF CHANGE**: 20250703

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stevens Raymond C
- **CENTRAL INDEX KEY:** 0001698149

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41608
- **FILM NUMBER:** 251106356

**MAIL ADDRESS:**
- **STREET 1:** 2200 PENNSYLVANIA AVENUE
- **STREET 2:** SUITE 800W
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20037
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (628) 229-9277

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stevens Raymond C<br><sub>(Last) (First) (Middle)</sub><br>C/O STRUCTURE THERAPEUTICS INC.<br>601 GATEWAY BLVD., SUITE 900<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-03-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF EXECUTIVE OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Structure Therapeutics Inc. [ GPCR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 2025-03-01 |  | F |  | 12495<sup>(2)</sup> | D | $7.9166 | 1121183 | D |  |
| Ordinary Shares<sup>(1)</sup> | 2025-07-01 |  | A<sup>(3)</sup> |  | 89697 | A | $0 | 1210880 | D |  |
| Ordinary Shares<sup>(1)</sup> | 2025-07-01 |  | F |  | 16050<sup>(2)</sup> | D | $6.8366 | 1194830 | D |  |
| Ordinary Shares<sup>(1)</sup> |  |  |  |  |  |  |  | 1554586 | I | See footnote<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| American Depositary Shares | <sup>(5)</sup> | 2025-05-21 |  | A<sup>(6)</sup> |  | 1000 |  | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares<sup>(1)</sup> | 3000 | $0 | 1000 | D |  |
| American Depositary Shares | <sup>(5)</sup> |  |  |  |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares<sup>(1)</sup> | 12000 |  | 4000 | I | See footnote<sup>(4)</sup> |

---

### Footnotes:

(1) The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

(2) Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

(3) On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria.  Certain of the performance criteria was determined to have been met effective July 1, 2025.  The shares subject to the PSUs vest as follows:  50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.

(4) By Raymond Stevens and Vivian Urena-Stevens, as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001.

(5) Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

(6) Voluntary reporting of the acquisition of 1,000 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

**Signature:** /s/ Jun Yoon, Attorney-in-Fact  
**Date:** 2025-07-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**